Related Experiment Video

Updated: May 12, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.2K

Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report

Toktam Faghihi1, Farahnak Assadi2

  • 1Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran and Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Clinical Therapeutics
|March 2, 2025
PubMed

Insights

Febuxostat shows promise for lowering uric acid in children with hyperuricemia. More research, including randomized trials, is needed to confirm its effectiveness and safety compared to allopurinol.

Area of Science:

  • Pediatric Nephrology
  • Pharmacology
  • Internal Medicine

Background:

  • Febuxostat is a xanthine oxidase inhibitor effective for lowering uric acid in adults.
  • Limited data exists on febuxostat's use in pediatric populations.
  • Hyperuricemia in children can stem from various etiologies.

Purpose of the Study:

  • To review current knowledge on the efficacy and safety of febuxostat in children with hyperuricemia.
  • To summarize findings from studies investigating febuxostat in pediatric patients.

Main Methods:

  • A comprehensive literature search was conducted across major databases (PubMed, Google Scholar, Embase, Web of Science) up to September 2024.
  • Included study types encompassed randomized controlled trials, observational studies, systematic reviews, meta-analyses, and retrospective studies.
  • Studies focused on children and adolescents with hyperuricemia from diverse causes, including comparisons with allopurinol.

Main Results:

  • Three studies evaluated febuxostat for hyperuricemia in children with conditions like tumor lysis syndrome (TLS), asymptomatic hyperuricemia, and gout.
  • Efficacy for asymptomatic hyperuricemia and gout was assessed in observational and retrospective studies.
  • One retrospective study compared febuxostat with allopurinol for TLS prevention.

Conclusions:

  • Febuxostat appears to be a promising agent for achieving therapeutic uric acid levels in pediatric patients.
  • Current evidence is insufficient to draw conclusions on the comparative efficacy and safety of febuxostat versus allopurinol in children.
  • Further randomized clinical trials are necessary to establish the definitive effectiveness and safety profile of febuxostat in this age group.
Abstract

Keywords:
AllopurinolChildrenFebuxostatGoutHyperuricemiaTumor lysis syndrome

More Related Videos

Methods for Analyzing the Impacts of Natural Uranium on In Vitro Osteoclastogenesis09:51

Methods for Analyzing the Impacts of Natural Uranium on In Vitro Osteoclastogenesis

Published on: January 30, 2018

8.1K
Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides08:46

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Published on: July 26, 2018

8.6K

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...